Trumenba Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

The safety of Trumenba was investigated in clinical studies that enrolled over 23,000 subjects, of which approximately 17,000 subjects received at least one dose of Trumenba administered alone or concomitantly with a licensed vaccine and over 6,000 control subjects received either saline alone, a licensed vaccine alone, or saline and a licensed vaccine.
Adverse reactions reported in clinical studies are listed in this section per system organ class, in decreasing order of seriousness.
Adverse reactions following booster vaccination in 301 subjects aged 15 to 23 years were similar to adverse reactions during the primary Trumenba vaccination series approximately 4 years earlier. (See Table 8.)

Click on icon to see table/diagram/image

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.

View ADR Reporting Link

Trumenba Adverse Reactions

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma